Results 51 to 60 of about 51,825 (261)
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]
Drug Des Devel TherHou L, Lin B, Ji X, Huang A.
europepmc +3 more sources
Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]
, 2020 Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark +2 more
core
Advanced Science, EarlyView.Aged HSF1 muscle‐specific knockout mice show deteriorated muscle atrophy and metabolic dysfunction, while active HSF1 overexpression improves muscle function via activating SIRT3 to deacetylate both PGC1α1 and PGC1α4, which boosts mitochondrial function and muscle hypertrophy in a fiber‐type specific manner, and induces FNDC5/Irisin for tissue ...
Jun Zhang +18 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in ...
Caroline J. Coats +35 more
doaj +1 more source
Rabbit models of heart disease. [PDF]
, 2008 Human heart disease is a major cause of death and disability. A variety of animal models of cardiac disease have been developed to better understand the etiology, cellular and molecular mechanisms of cardiac dysfunction and novel therapeutic strategies ...
Bers, Donald M, Pogwizd, Steven M
core
Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders [PDF]
, 2014 The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for
Olson, Eric S., van Rooij, Eva
core +1 more source
Cardiac myosin inhibitors in hypertrophic cardiomyopathy
Journal of Cardiovascular ImagingAbstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim, Jaehyun, Kim, Hyung-Kwan
openaire +1 more source
A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors
Cardiologia Hungarica, 2023 In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the core molecular defect of the disease, by selectively ...
Pálinkás, Eszter Dalma +2 more
openaire +2 more sources
Advanced Science, EarlyView.Scars exhibit vascular abnormal alterations, including upregulated NRP1 expression in endothelial cells, increased vascular density and branching, compromised vessel wall integrity, and incomplete pericyte coverage. Therapeutic targeting of NRP1 through hydrogel spray delivery offers a promising approach to normalize aberrant vasculature and prevent ...
Yu Wang +11 more
wiley +1 more source
Frontiers in Cardiovascular MedicineMavacamten is a first-in-class cardiac myosin ATPase inhibitor, approved by the United States Food and Drug Administration for the treatment of hypertrophic cardiomyopathy with obstructive physiology (oHCM).
Daniel Seung Kim +92 more
doaj +1 more source